...
首页> 外文期刊>Scientific reports. >Loss of the 14-3-3σ is essential for LASP1-mediated colorectal cancer progression via activating PI3K/AKT signaling pathway
【24h】

Loss of the 14-3-3σ is essential for LASP1-mediated colorectal cancer progression via activating PI3K/AKT signaling pathway

机译:14-3-3σ的损失对于通过激活PI3K / AKT信号通路的Lasp1介导的结肠直肠癌进展至关重要

获取原文

摘要

LIM and SH3 protein 1 (LASP1) can promote colorectal cancer (CRC) progression and metastasis, but the direct evidence that elucidates the molecular mechanism remains unclear. Here, our proteomic data showed that LASP1 interacted with 14-3-3σ and decreased the expression of 14-3-3σ in CRC. Deletion of 14-3-3σ was required for LASP1-mediated CRC cell aggressiveness. In vitro gain- and loss-of-function assays showed that 14-3-3σ suppressed the ability of cell migration and decreased the phosphorylation of AKT in CRC cells. We further observed clearly co-localization between AKT and 14-3-3σ in CRC cells. Treatment of PI3K inhibitor LY294002 markedly prevented phosphorylation of AKT and subsequently counteract aggressive phenotype mediated by siRNA of 14-3-3σ. Clinically, 14-3-3σ is frequently down-regulated in CRC tissues. Down-regulation of 14-3-3σ is associated with tumor progression and poor prognosis of patients with CRC. Multivariate analysis confirmed low expression of 14-3-3σ as an independent prognostic factor for CRC. A combination of low 14-3-3σ and high LASP1 expression shows a worse trend with overall survival of CRC patients. Our research paves the path to future investigation of the LASP1-14-3-3σ axis as a target for novel anticancer therapies of advanced CRC.
机译:LIM和SH3蛋白1(LAPAP)可以促进结直肠癌(CRC)进展和转移,但阐明分子机制的直接证据仍不清楚。在这里,我们的蛋白质组学数据显示Lasp1与14-3-3σ相互作用并降低CRC中14-3-3σ的表达。 Lasp1介导的CRC细胞侵略性需要缺失14-3-3σ。体外增益和功能丧失测定表明,14-3-3σ抑制细胞迁移的能力并降低了CRC细胞中Akt的磷酸化。我们进一步观察到CRC细胞中Akt和14-3-3σ之间的明确定位。 PI3K抑制剂LY294002的治疗明显防止AKT的磷酸化,随后抵消SiRNA介导的14-3-3σ介导的侵袭性表型。临床上,14-3-3σ经常在CRC组织中下调。 14-3-3σ的下调与CRC患者的肿瘤进展和不良预后有关。多变量分析证实了14-3-3σ的低表达作为CRC的独立预后因子。低14-3-3σ和高LASP1表达的组合显示了CRC患者的整体存活率较差的趋势。我们的研究铺平了LAP1-14-3-3σ轴的未来调查的途径作为高级CRC的新型抗癌疗法的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号